A U.S. patient guide to osteoporosis injection treatments — comparing Prolia, Reclast, Forteo, and Evenity, including Medicare coverage, costs, and side effects.If your healthcare provider in the United States has recommended bone density injections for osteoporosis or osteopenia, you likely have questions about how these treatments work, what they cost, whether Medicare covers them, and what to expect over the coming years. This guide walks U.S. patients through every major FDA-approved injection option so you can have a more informed conversation with your doctor.
U.S. context: All medications discussed below are FDA-approved and commonly prescribed in the United States. Coverage and pricing reflect the U.S. healthcare system, including Medicare Part B and most private insurance plans. This guide is especially relevant for postmenopausal women and adults aged 50+ with confirmed osteoporosis on a DEXA scan (T-score ≤ −2.5).
Understanding Bone Density Injection Treatments
Bone density injections are commonly used in the management of osteoporosis and are generally categorized into two main types based on how they work in the body.
Anti-resorptive treatments (slowing bone loss)
These medications help reduce the rate at which bone is broken down, supporting overall bone density over time. Commonly prescribed U.S. options include:
Denosumab (Prolia®) — a subcutaneous injection given every 6 months. Clinical studies show it reduces vertebral fracture risk by roughly 68% over 3 years in postmenopausal women with osteoporosis.
Zoledronic acid (Reclast®) — an intravenous (IV) infusion, usually once per year. Shown to reduce hip fractures by about 41% over 3 years.
Anabolic treatments (supporting bone formation)
Anabolic therapies work by helping stimulate new bone formation and may be recommended for patients with higher fracture risk or more advanced bone loss:
Teriparatide (Forteo®) — a daily self-injection, typically for up to 2 years.
Romosozumab (Evenity®) — monthly injections for 12 months, for severe osteoporosis.
Your doctor will evaluate your DEXA bone-density results, fracture risk, and medical history before recommending a specific therapy.
Quick Comparison: U.S. Osteoporosis Injections
Medication Type How it’s given Frequency Avg. U.S. cost (before insurance)*
Prolia (denosumab) Anti-resorptive Subcutaneous Every 6 months ~$1,400 / dose
Reclast (zoledronic acid) Anti-resorptive IV infusion Once per year ~$1,100 / infusion
Forteo (teriparatide) Anabolic Daily self-injection Up to 2 years ~$3,500 / month
Evenity (romosozumab) Anabolic Monthly injection 12 months ~$2,200 / month
*Estimated U.S. list prices; actual out-of-pocket cost depends on Medicare/private insurance and patient assistance programs.
Does Medicare Cover Bone Density Injections?
For U.S. patients, this is often the deciding question. Medicare Part B generally covers FDA-approved osteoporosis injections for qualified beneficiaries — including postmenopausal women and certain other adults — usually after a bone-density test confirms osteoporosis. Coverage typically applies when the injection is administered in a clinical setting. Copays, deductibles, and prior-authorization rules vary by plan, so confirm specifics with your provider and insurer before starting treatment.
Preparing for Treatment: Health & Dental Considerations
Before starting osteoporosis injections, many U.S. providers recommend a general health and dental evaluation. This may include:
Reviewing your dental history (some anti-resorptive drugs carry a rare risk of osteonecrosis of the jaw)
Completing any invasive dental procedures before treatment begins
Ensuring overall oral health is stable
Maintaining good oral hygiene and routine dental visits is generally recommended throughout treatment.
Calcium, Vitamin D, and Bone Health Support
Adequate calcium and vitamin D intake is a key part of any U.S. bone-health plan. Your provider may recommend:
Calcium intake of about 1,000–1,200 mg/day from diet and/or supplements (NIH guidance for adults 50+)
Vitamin D supplementation based on blood-test results (often 800–1,000 IU/day)
Periodic lab testing to monitor nutrient levels
Staying Consistent With Treatment
Some osteoporosis medications, particularly denosumab (Prolia®), must follow a strict schedule. Missing a dose can lead to rapid bone loss and rebound fracture risk. It’s important to:
Follow your injection schedule as directed
Attend all follow-up appointments and DEXA scans
Discuss any delays with your healthcare provider promptly
Possible Side Effects
Symptoms vary by medication. Some patients report:
Temporary flu-like symptoms after IV treatments such as Reclast®
Mild muscle or joint discomfort with certain injectable therapies
Short-term injection-site reactions
Discuss any side effects with your provider as part of ongoing treatment planning.
Frequently Asked Questions
Does Medicare cover bone density injections for osteoporosis?
Yes. Medicare Part B typically covers FDA-approved osteoporosis injections (such as Prolia) for qualified beneficiaries after a bone-density test confirms osteoporosis. Copays and rules vary by plan.
How long do bone density injections take to work?
Most patients see measurable bone-density improvements within 12 months, though fracture-risk reduction can begin earlier. Treatment is typically individualized over 3–5 years based on DEXA results.
Are bone density injections painful?
Most subcutaneous injections use very small needles and are well tolerated. IV infusions involve a brief needle insertion followed by a monitored infusion.
Can I continue normal daily activities during treatment?
Many patients continue normal activities during osteoporosis treatment. Your provider may give specific guidance based on your condition.
Medical Disclaimer: This article is for general informational purposes only and does not constitute medical advice. It is not a substitute for professional diagnosis or treatment by a licensed U.S. healthcare provider. Always consult your doctor before starting, changing, or stopping any osteoporosis treatment. This page was last medically reviewed on July 6, 2026.
References & Sources
U.S. National Institutes of Health (NIH) Osteoporosis Overview — Osteoporosis and Related Bone Diseases National Resource Center.
U.S. FDA prescribing information for Prolia (denosumab), Reclast (zoledronic acid), Forteo (teriparatide), and Evenity (romosozumab).
Centers for Medicare & Medicaid Services (CMS) — Medicare Part B coverage of osteoporosis treatments.
National Osteoporosis Foundation (NOF) — Clinician’s Guide to Prevention and Treatment of Osteoporosis.
E-E-A-TYMYL-compliantUS-geo